J. Goldman & Co’s Coherus Oncology CHRS Stock Holding History

J. Goldman & Co’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,300	Closed	-$207K	–	387
2020 Q3	$207K	Buy	+11,300	New	+$210K	0.01%	283

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

J. Goldman & Co's CHRS Position: Q3 2020 in Review

J. Goldman & Co sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 149,986 shares — an estimated $2.79M sold.

J. Goldman & Co first reported a position in CHRS in Q4 2019 and held it in 3 quarters. The position peaked at $2.68M in Q2 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

J. Goldman & Co reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
J. Goldman & Co sold 149,986 Coherus Oncology shares in Q3 2020, an estimated $2.79M.
J. Goldman & Co first reported a position in Coherus Oncology in Q4 2019 and held it in 3 quarters.
J. Goldman & Co's Coherus Oncology position peaked at $2.68M in Q2 2020.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on J. Goldman & Co's 13F filing for Q3 2020, filed 16 Nov 2020.